Activity of Delafloxacin When Tested Against Bacterial Surveillance Isolates Collected in the US and Europe During 2014–2016 as Part of a Global Surveillance Program

BACKGROUND: Delafloxacin (DLX) is an investigational anionic fluoroquinolone with an NDA that is under US FDA review to treat acute bacterial skin and skin structure infections and is undergoing Phase 3 studies to treat community-acquired bacterial pneumonia. METHODS: A total of 36,683 Gram-positive...

Descripción completa

Detalles Bibliográficos
Autores principales: Flamm, Robert K, Shortridge, Dee, Huband, Michael D, McCurdy, Sandra, Pfaller, Michael A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630863/
http://dx.doi.org/10.1093/ofid/ofx163.918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630863/
http://dx.doi.org/10.1093/ofid/ofx163.918

Ejemplares similares